Harmony Biosciences jumps as co announces positive results from sleep disorder drug study

Shares of Harmony Biosciences HRMY.O rise 2.2% to $35.07

Co reports positive results from key study on pitolisant GR, a gastro-resistant tablet formulation of its sleep disorder drug Wakix designed to withstand stomach acid and dissolve in the intestine

HRMY says results support plan to file for U.S. approval in early 2026; aims for FDA decision in Q1 2027

New GR tablets shown to work the same as current Wakix tablets; no new safety issues found

Study also showed all patients could start at full dose without gradual increase

HRMY stock up 0.5%% YTD, including session moves